|30th December 2020||Thomas Woiwode||1,347,709||Open or private purchase||$3.71||$5,000,000.39|
|14th December 2020||Thomas Woiwode||12,783||Other acquisition or disposition||$0.00|
|20th October 2020||Thomas Woiwode||198,485||Conversion of derivative||$0.00|
|20th October 2020||Thomas Woiwode||200,000||Open or private purchase||$15.00||$3,000,000.00|
|20th October 2020||Thomas Woiwode||463,959||Conversion of derivative||$0.00|
|20th October 2020||Thomas Woiwode||198,839||Conversion of derivative||$0.00|
|20th October 2020||Thomas Woiwode||2,145,991||Conversion of derivative||$0.00|
|20th October 2020||Thomas Woiwode||85,065||Conversion of derivative||$0.00|
|17th August 2020||Erin Jones||10,000||Exercise of derivative||$0.35||$3,450.00|
|3rd March 2020||Thomas Woiwode||1,049,175||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Gritstone Oncology, Inc. is a clinical-stage biotechnology company. The company is developing the next generation of cancer immunotherapies to fight multiple cancer types.